EPA to consider non-CFC inhaler market share "potential" in processing CFC exemption requests.
Executive Summary
EPA TO CONSIDER "POTENTIAL" MARKET PENETRATION OF NON-CFC CONTAINING asthma products in processing requests for exemptions for chlorofluorocarbon-containing metered-dose inhalers, Environmental Protection Agency Essential Uses Program Manager Nina Bonnelycke told the International Conference on Ozone Protection Technologies in Washington, D.C. Oct. 23. EPA is "going to include consideration of [approved, CFC-free] alternatives and their potential for market penetration in its estimate" of companies' CFC needs that it provides to the United Nations Environment Program this year, Bonnelycke said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth